WO2006061418A3 - Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus - Google Patents

Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus Download PDF

Info

Publication number
WO2006061418A3
WO2006061418A3 PCT/EP2005/056610 EP2005056610W WO2006061418A3 WO 2006061418 A3 WO2006061418 A3 WO 2006061418A3 EP 2005056610 W EP2005056610 W EP 2005056610W WO 2006061418 A3 WO2006061418 A3 WO 2006061418A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hypersecretion
agr2
mucus
agents useful
Prior art date
Application number
PCT/EP2005/056610
Other languages
English (en)
Other versions
WO2006061418A2 (fr
Inventor
Lutz Zeitlmann
Johannes Grosse
Klaus Dembowsky
Andreas Popp
Original Assignee
Ingenium Pharmaceuticals Ag
Lutz Zeitlmann
Johannes Grosse
Klaus Dembowsky
Andreas Popp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenium Pharmaceuticals Ag, Lutz Zeitlmann, Johannes Grosse, Klaus Dembowsky, Andreas Popp filed Critical Ingenium Pharmaceuticals Ag
Priority to EP05816225A priority Critical patent/EP1831367A2/fr
Publication of WO2006061418A2 publication Critical patent/WO2006061418A2/fr
Publication of WO2006061418A3 publication Critical patent/WO2006061418A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne notamment l'extinction génique du gène Agr2 par des ARN interférents courts (ARNic). En outre, étant donné l'implication du gène Agr2 dans la production de mucus production, cette invention concerne également des compositions pharmaceutiques utiles comme médicaments dans des procédés de prévention, d'amélioration ou de traitement d'états médicaux associés à l'hyperproduction/hypersécrétion de mucus, en particulier dans les voies respiratoires. De nouveaux ARNic utiles dans ces procédés et de nouvelles compositions pharmaceutiques sont également décrites. Cette invention concerne en outre des procédés de criblage d'ARNic additionnels capables d'éteindre l'expression du gène Agr2.
PCT/EP2005/056610 2004-12-09 2005-12-08 Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus WO2006061418A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05816225A EP1831367A2 (fr) 2004-12-09 2005-12-08 Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63458704P 2004-12-09 2004-12-09
US60/634,587 2004-12-09

Publications (2)

Publication Number Publication Date
WO2006061418A2 WO2006061418A2 (fr) 2006-06-15
WO2006061418A3 true WO2006061418A3 (fr) 2006-08-03

Family

ID=36297388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056610 WO2006061418A2 (fr) 2004-12-09 2005-12-08 Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus

Country Status (2)

Country Link
EP (1) EP1831367A2 (fr)
WO (1) WO2006061418A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415088B2 (en) 2011-02-25 2016-08-16 The Board Of Trustees Of The Leland Stanford Junior University Use of AGR3 for treating cancer
WO2021142245A1 (fr) * 2020-01-10 2021-07-15 Translate Bio, Inc. Composés, compositions pharmaceutiques et méthodes pour moduler l'expression de la muc5b dans des cellules et des tissus pulmonaires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041627A1 (fr) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Polypeptides secretes presentant une homologie avec les proteines de la glande cementaire du xenopus
WO2002010449A2 (fr) * 2000-07-28 2002-02-07 Compugen Inc. Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome
WO2004031239A2 (fr) * 2002-10-02 2004-04-15 The University Of Liverpool Composes inducteurs de metastases
WO2004056858A2 (fr) * 2002-12-23 2004-07-08 Ingenium Pharmaceuticals Ag Methodes et agents pour le diagnostic et la prevention, l'amelioration ou le traitement de troubles lies aux cellules caliciformes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041627A1 (fr) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Polypeptides secretes presentant une homologie avec les proteines de la glande cementaire du xenopus
WO2002010449A2 (fr) * 2000-07-28 2002-02-07 Compugen Inc. Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome
WO2004031239A2 (fr) * 2002-10-02 2004-04-15 The University Of Liverpool Composes inducteurs de metastases
WO2004056858A2 (fr) * 2002-12-23 2004-07-08 Ingenium Pharmaceuticals Ag Methodes et agents pour le diagnostic et la prevention, l'amelioration ou le traitement de troubles lies aux cellules caliciformes

Also Published As

Publication number Publication date
EP1831367A2 (fr) 2007-09-12
WO2006061418A2 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2007090569A8 (fr) Composition sanguine conditionnée et son procédé de préparation
TN2011000415A1 (en) Pharmaceutical composition comprising a sglt2 inhibitor a dpp-i v inhibitor and optionally a further antidiabetic agent and uses thereof
WO2008011363A3 (fr) Compositions contenant de la quercétine
WO2009050506A3 (fr) Combinaison 059
WO2005077093A3 (fr) Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees
MY161472A (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2007044950A3 (fr) Formes cristallines de docetaxel et leurs processus de preparation
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2006008028A8 (fr) Nouvelles 6-formyltetrahydropteridines, procede de production et utilisation de ces dernieres comme medicaments, notamment contre le cancer
WO2007029249A3 (fr) Oligoribonucleotides et leurs methodes d'utilisation dans le traitement des maladies cardio-vasculaires
WO2007146425A3 (fr) Composés et procédés destinés au traitement prophylactique d'une anémie induite par une chimiothérapie
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2006023452A3 (fr) Analogues de la cyclosporine utilises pour le traitement de troubles immunoregulateurs et de maladies respiratoires
WO2011075606A3 (fr) Variants de polypeptide hyperglycosylé et procédés d'utilisation
WO2008048121A3 (fr) Composés et compositions
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
WO2005092878A3 (fr) Analogues de schweinfurthines
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2006019978A3 (fr) Compositions et procedes pour le diagnostic et le traitement d'epilepsie
WO2008118792A3 (fr) Lymphocytes t gamma delta et procédés de traitement de problèmes liés à l'interleukine-17
WO2006061418A3 (fr) Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus
WO2008066770A3 (fr) Composés activateurs de l'ace2 et procédés d'utilisation de ceux-ci
WO2005009361A3 (fr) Methode de traitement a l'argatroban pour des patients souffrant de thrombocytopenie induite par l'heparine
WO2005107464A3 (fr) Composes et compositions utilises en tant qu'inhibiteurs de la cathepsine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005816225

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005816225

Country of ref document: EP